Update on actinic keratosis in clinical trial experience with imiquimod.
Actinic keratoses (AK) is a sun induced cutaneous lesion, currently considered as a squamous cell carcinoma in situ that has the potential to progress to invasive SCC. To treat them, numerous, ablative and no ablative, therapeutic approaches exist. Among them, imiquimod, a toll like receptor agonist, recently approved to treat them in the US and Europe, has demonstrated to be effective and safe with an acceptable tolerability in the treatment of these lesions. In this article the results of several high quality RCT are analysed.
Ferrándiz
C
C
Hospital Universitario Germans Trias I Pujol, Universidad Autónoma de Barcelona, Badalona, Spain. cferrandiz.germanstrias@gencat.net
D000634:Aminoquinolines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D007642:Keratosis / Q000188:drug therapy*; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014466:Ultraviolet Rays / Q000009:adverse effects
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod